Active	Status	Sponsor type	Region	Phase	Filter
12 Active 0 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nath, Rajneesh
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage	Recruiting	3	450	US	DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	12/22	12/22
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL Presentation of P1 data from P1/2 trial for CLL at ASH 2018 Dec 2018 - Dec 2018: Presentation of P1 data from P1/2 trial for CLL at ASH 2018 From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] Dec 2018 - Dec 2018: From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] More	Recruiting	1/2	320	Canada, US	JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax	Juno Therapeutics, a Subsidiary of Celgene	Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic	11/27	11/27
NCT04649112: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies	Completed	1	13	US	PBCAR19B, Allogeneic Anti-CD19 CAR T cells	Precision BioSciences, Inc.	CD19 Expressing Malignancies, Hematologic Malignancy	12/22	09/23
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL	Recruiting	1	129	US, RoW	Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine	Imugene Limited	Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia	06/25	06/27
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML	Recruiting	1	50	US	Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®	Oryzon Genomics S.A.	Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory	11/25	11/25
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT	Completed	1	60	US	Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo	Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center	Allogeneic Hematopoietic Stem Cell Transplantation	07/24	07/24
Katsanis, Emmanuel
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)